Orchestra BioMed Financials
| OBIO Stock | 5.77 0.33 6.07% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.35 | 7.9509 |
|
|
The essential information of the day-to-day investment outlook for Orchestra BioMed includes many different criteria found on its balance sheet. An individual investor should monitor Orchestra BioMed's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Orchestra BioMed.
Net Income |
|
Orchestra | Select Account or Indicator |
Understanding current and past Orchestra BioMed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Orchestra BioMed's financial statements are interrelated, with each one affecting the others. For example, an increase in Orchestra BioMed's assets may result in an increase in income on the income statement.
Orchestra BioMed Stock Summary
Orchestra BioMed competes with CytomX Therapeutics, Assembly Biosciences, Achilles Therapeutics, Instil Bio, and NextCure. Orchestra BioMed is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US68572M1062 |
| CUSIP | G4411D109 68572M106 |
| Location | Pennsylvania; U.S.A |
| Business Address | 150 Union Square |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | orchestrabiomed.com |
| Phone | 212 862 5797 |
Orchestra BioMed Key Financial Ratios
| Return On Equity | -0.92 | ||||
| Operating Margin | (16.56) % | ||||
| Price To Sales | 78.12 X | ||||
| Revenue | 2.76 M | ||||
| EBITDA | (51.22 M) |
Orchestra Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orchestra BioMed's current stock value. Our valuation model uses many indicators to compare Orchestra BioMed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orchestra BioMed competition to find correlations between indicators driving Orchestra BioMed's intrinsic value. More Info.Orchestra BioMed Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Orchestra BioMed's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orchestra BioMed's earnings, one of the primary drivers of an investment's value.Orchestra BioMed Holdings Systematic Risk
Orchestra BioMed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Orchestra BioMed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Orchestra BioMed Holdings correlated with the market. If Beta is less than 0 Orchestra BioMed generally moves in the opposite direction as compared to the market. If Orchestra BioMed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Orchestra BioMed Holdings is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Orchestra BioMed is generally in the same direction as the market. If Beta > 1 Orchestra BioMed moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Orchestra BioMed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Orchestra BioMed's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Orchestra BioMed growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Orchestra BioMed November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Orchestra BioMed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Orchestra BioMed Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Orchestra BioMed Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Orchestra Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Orchestra BioMed's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 25.42 | |||
| Value At Risk | (7.67) | |||
| Potential Upside | 7.24 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.